Role of Recombinant Human Bone Morphogenetic Protein-2 on Hindfoot Arthrodesis

Hreha, Jeremy; Krell, Ethan S.

doi:10.1016/j.fcl.2016.07.001

Cited by 13 publications

(9 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Developments in bone tissue engineering and bone biology have revealed the unique advantages of bone morphogenetic proteins (BMPs) for bone tissue repair. Members of the transforming growth factor superfamily, BMPs, promote bone healing by inducing mesenchymal stem cells to differentiate into osteoblasts [ 8 , 9 ]. Two BMPs (recombinant BMP 2 and recombinant BMP 7) have been approved for clinical use by the US Food and Drug Administration (USDA) [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Comparison of bone morphogenetic protein and autologous grafting in the treatment of limb long bone nonunion: a systematic review and meta-analysis

Zhou

Duan

et al. 2020

J Orthop Surg Res

View full text Add to dashboard Cite

Background: Bone morphogenetic proteins (BMPs) have strong bone induction properties and can promote healing of fractures and other defects. However, BMP treatment efficacy for long bone nonunion remains controversial. The aim of this meta-analysis was to synthetically evaluate the advantages and disadvantages of BMP plus bone grafting (observation group) versus autologous bone grafting (control group) for limb long bone nonunion. Methods: PubMed, Embase, Web of Science, Cochrane Library, OVID, CNKI, Weipu Journal, Chinese Biomedical Literature, and WanFang were searched for randomized and non-randomized controlled trials published before November 2019. A meta-analysis of outcome indicators was performed using RevMan 5.3 and Stata 12.0. Results: Five randomized and four non-randomized controlled trials involving 30-124 cases were included, with a total of 655 nonunion cases. There were no significant group differences in postoperative healing rate, infection, and secondary operation rates (P > 0.05), but the study group demonstrated significantly shorter mean healing time (WMD = − 1.27, 95%CI − 1.67 to − 0.88, P < 0.00001), a greater frequency of excellent/good post-treatment limb function (RR = 1.18, 95%CI 1.01-1.39, P = 0.04), and lower intraoperative blood loss (P < 0.05). Alternatively, the hospitalization cost was significantly higher in the study group (P < 0.01). Conclusions: Bone morphogenetic protein is a viable alternative to autologous bone grafting, with potential advantages of accelerated fracture healing and improved postoperative function.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Comparison of bone morphogenetic protein and autologous grafting in the treatment of limb long bone nonunion: a systematic review and meta-analysis

Zhou

Duan

et al. 2020

J Orthop Surg Res

View full text Add to dashboard Cite

show abstract

“…Currently, the Food and Drug Administration (FDA) approves the use of rhBMP-2 for spinal fusions, acute trauma of the tibia, and head and neck bone grafting procedures [12•]. The use of BMP in foot and ankle injuries is off-label, but there are studies indicating a role for BMP in ankle arthrodesis and bony non-unions [10][11][12][13]. Though no recent study currently focuses solely on its use in foot and ankle trauma, BMP does serve as an adjuvant during treatment of the complications of trauma, such as arthritis and non-unions [10][11][12][13][14].…”

Section: Bone Morphogenetic Protein-2 and Platelet-derived Growth Factormentioning

confidence: 99%

The role of biologic in foot and ankle trauma—a review of the literature

Zhao

Carney

Chambers

et al. 2018

Curr Rev Musculoskelet Med

View full text Add to dashboard Cite

The most recent studies have shown benefits for biologic use in patients predisposed to poor bone and soft tissue healing. Biologics have shown benefit in treating soft tissue injuries such as Achilles ruptures as well as the complications of trauma such as non-unions and osteoarthritis. Biologics have shown some benefit in improving functional and pain scores, as well as reducing time to heal in foot and ankle traumatic injuries, with particular success shown with patients that have risk factors for poor healing. As the use of biologics continues to increase, there is a need for high-level studies to confirm early findings of lower level reports.

show abstract

Section: Operative Versteifung Von Gelenkenunclassified

“…Trotz moderner Operationstechniken verbleibt ein hohes Risiko der Pseudarthrosenbildung nach operativer Versteifung des Rückfußes [18]. Die zusätzliche Verwendung von BMP-2 in der Versteifung des Rückfußes führte zu einer signifikant besseren Heilungsrate [18]. Daher stellt die Verwendung von BMP-2 eine valide und klinisch effiziente zusätzliche Therapieoption in der Rückfußversteifung dar [19].…”

Section: Operative Versteifung Von Gelenkenunclassified

Aktueller Stellenwert der Behandlung mit Wachstumsfaktoren

Haubruck¹,

Schmidmaier²

2018

Orthopädie und Unfallchirurgie up2date

View full text Add to dashboard Cite

Role of Recombinant Human Bone Morphogenetic Protein-2 on Hindfoot Arthrodesis

Cited by 13 publications

References 64 publications

RETRACTED ARTICLE: Comparison of bone morphogenetic protein and autologous grafting in the treatment of limb long bone nonunion: a systematic review and meta-analysis

RETRACTED ARTICLE: Comparison of bone morphogenetic protein and autologous grafting in the treatment of limb long bone nonunion: a systematic review and meta-analysis

The role of biologic in foot and ankle trauma—a review of the literature

Aktueller Stellenwert der Behandlung mit Wachstumsfaktoren

Contact Info

Product

Resources

About